Status:
COMPLETED
UCSF BP Activate Letter Study
Lead Sponsor:
University of California, San Francisco
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The BP Activate Study aims to assess the effectiveness of the BP Report letter with personalized BP medication recommendations, compared with Control letters and no intervention, at shortening time to...
Detailed Description
The BP Activate Study is a randomized quality improvement trial. We will deliver one of two versions of a letter to established English-speaking primary care patients at Mt Zion with uncontrolled hype...
Eligibility Criteria
Inclusion
- Patient is a primary care patient of a clinician in a general internal medicine clinic who has agreed to have their patients participate in the study
- Lowest SBP\>140 or lowest DBP\>90 at last visit in general internal medicine clinic
- Last visit in general internal medicine clinic was \< 2 years ago
- EngageRx algorithm determines that a medication intensification step is indicated
Exclusion
- Primary language is not English
- Patient's provider indicates (through an active opt-out process) that they do not want the patient to receive a BP Activate letter
Key Trial Info
Start Date :
July 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
484 Patients enrolled
Trial Details
Trial ID
NCT06152094
Start Date
July 20 2023
End Date
December 31 2024
Last Update
January 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143